Total Payments
$7,966
2024 Payments
$432.94
Companies
50
Transactions
261
Medicare Patients
1,192
Medicare Billing
$217,976
Payment Breakdown by Category
Food & Beverage$6,012 (75.5%)
Education$1,455 (18.3%)
Other$498.50 (6.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,012 | 232 | 75.5% |
| Education | $1,455 | 24 | 18.3% |
| Long term medical supply or device loan | $498.50 | 5 | 6.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,195 | 33 | $0 (2024) |
| Janssen Biotech, Inc. | $803.80 | 26 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $535.06 | 19 | $0 (2024) |
| Incyte Corporation | $528.87 | 11 | $0 (2022) |
| Genentech USA, Inc. | $508.28 | 7 | $0 (2019) |
| Astellas Pharma US Inc | $385.63 | 8 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $385.57 | 16 | $0 (2024) |
| Lilly USA, LLC | $303.60 | 15 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $290.47 | 5 | $0 (2020) |
| PFIZER INC. | $281.05 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $432.94 | 21 | AstraZeneca Pharmaceuticals LP ($83.65) |
| 2023 | $963.71 | 26 | Novartis Pharmaceuticals Corporation ($317.18) |
| 2022 | $1,181 | 48 | Novartis Pharmaceuticals Corporation ($288.86) |
| 2021 | $368.93 | 12 | Janssen Biotech, Inc. ($113.11) |
| 2020 | $485.74 | 17 | Pharmacyclics LLC, An AbbVie Company ($125.00) |
| 2019 | $1,520 | 50 | AstraZeneca Pharmaceuticals LP ($263.46) |
| 2018 | $1,039 | 33 | Astellas Pharma US Inc ($221.27) |
| 2017 | $1,974 | 54 | Genentech USA, Inc. ($486.05) |
All Payment Transactions
261 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $16.71 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Genetically Defined Disease | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $32.60 | General |
| Category: Oncology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Oncology | ||||||
| 10/07/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/02/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $18.36 | General |
| Category: HORMONE THERAPY | ||||||
| 09/21/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: Oncology | ||||||
| 09/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: Oncology | ||||||
| 08/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: Oncology | ||||||
| 08/09/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: Oncology | ||||||
| 08/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.12 | General |
| Category: Oncology | ||||||
| 07/10/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Oncology | ||||||
| 06/12/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $25.20 | General |
| 02/28/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: Oncology | ||||||
| 02/28/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.25 | General |
| Category: Oncology | ||||||
| 02/05/2024 | E.R. Squibb & Sons, L.L.C. | AUGTYRO (Drug) | Food and Beverage | Cash or cash equivalent | $22.82 | General |
| Category: Oncology | ||||||
| 01/31/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, COMIRNATY | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: Oncology | ||||||
| 12/01/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $34.13 | General |
| Category: Oncology | ||||||
| 10/04/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Oncology | ||||||
| 09/21/2023 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 08/11/2023 | SOBI, INC | Doptelet (Drug) | Education | In-kind items and services | $61.99 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 393 | 16,517 | $243,175 | $72,221 |
| 2022 | 11 | 330 | 11,273 | $166,935 | $50,997 |
| 2021 | 8 | 263 | 1,284 | $187,337 | $60,539 |
| 2020 | 7 | 206 | 629 | $116,310 | $34,220 |
Total Patients
1,192
Total Services
29,703
Medicare Billing
$217,976
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 75 | 507 | $129,792 | $39,989 | 30.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 21 | 146 | $38,690 | $8,787 | 22.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $12,818 | $5,076 | 39.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 34 | 46 | $13,340 | $5,047 | 37.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 18 | 131 | $14,934 | $3,536 | 23.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 73 | 347 | $3,123 | $2,915 | 93.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 74 | 349 | $8,027 | $2,656 | 33.1% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 20 | 14,601 | $14,601 | $2,335 | 16.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 18 | 114 | $5,814 | $1,437 | 24.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 13 | 22 | $1,716 | $420.92 | 24.5% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 13 | 220 | $320.00 | $21.59 | 6.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 61 | 361 | $92,416 | $29,326 | 31.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 18 | 87 | $23,055 | $5,797 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 31 | 40 | $11,600 | $4,603 | 39.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 19 | 19 | $9,006 | $3,720 | 41.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 66 | 265 | $6,095 | $2,034 | 33.4% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2022 | 17 | 10,100 | $10,100 | $1,660 | 16.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 17 | 57 | $6,498 | $1,635 | 25.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 17 | 102 | $5,202 | $1,368 | 26.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 61 | 173 | $1,557 | $512.43 | 32.9% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 12 | 13 | $1,014 | $263.34 | 26.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2022 | 11 | 56 | $392.00 | $79.23 | 20.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 66 | 473 | $121,088 | $38,548 | 31.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 32 | 32 | $15,168 | $6,652 | 43.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 11 | 67 | $17,755 | $4,886 | 27.5% |
About Dr. Muhammad Kafeel, M.D
Dr. Muhammad Kafeel, M.D is a Hospice and Palliative Medicine healthcare provider based in Richmond Hill, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/02/2009. The National Provider Identifier (NPI) number assigned to this provider is 1174756423.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Muhammad Kafeel, M.D has received a total of $7,966 in payments from pharmaceutical and medical device companies, with $432.94 received in 2024. These payments were reported across 261 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($6,012).
As a Medicare-enrolled provider, Kafeel has provided services to 1,192 Medicare beneficiaries, totaling 29,703 services with total Medicare billing of $217,976. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospice and Palliative Medicine
- Other Specialties Hematology & Oncology
- Location Richmond Hill, NY
- Active Since 09/02/2009
- Last Updated 09/12/2024
- Taxonomy Code 207RH0002X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1174756423
Products in Payments
- IMBRUVICA (Drug) $404.94
- KISQALI (Drug) $307.56
- Imbruvica (Drug) $290.47
- TAGRISSO (Drug) $269.78
- Avastin (Biological) $266.71
- OPDIVO (Biological) $265.33
- Vascepa (Drug) $249.07
- DARZALEX (Biological) $222.03
- KEYTRUDA (Biological) $206.26
- IMFINZI (Drug) $199.58
- PROMACTA (Drug) $186.16
- JAKAFI (Drug) $167.36
- AFINITOR (Drug) $164.61
- VELCADE (Drug) $162.00
- TASIGNA (Drug) $160.38
- XTANDI (Drug) $147.25
- VERZENIO (Drug) $137.47
- CYRAMZA (Drug) $131.11
- Alecensa (Biological) $125.00
- Vemlidy (Drug) $125.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.